AbbVie's closely watched schizophrenia drug fails two studies, shares slide
By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a ...
BioPharma Dive9 小时
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...
Mint1 小时
To cope with dementia, seniors are turning to cannabis
Typically, they are treated with antipsychotics. But those have side effects including severe constipation, confusion and ...
news.marketersmedia20 小时
Veterans Day: CCHR Calls for Safeguards Against Drugging & Electroshocking Vets
The mental health watchdog says the VA and DoD waste billions of dollars on treatments that contribute to high suicide rates, ...
Le Lézard12 小时
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
AbbVie today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute ...
Nursing Times15 小时
Orthostatic hypotension 2: effect of orthostatic hypotension on falls risk
Factors associated with ageing that can increase falls risk include loss of muscle strength and balance, orthostatic hypotension, and visual and functional impairments. Older people may also have ...